<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html lang="en">

<head>
  <title>Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov</title>
    <meta name="robots" content="noindex,nofollow"/>
    <meta http-equiv="Content-Type" content="text/html;charset=UTF-8"/>
    <link href="/ct2/show/NCT00697515" rel="canonical"/>
    <link href="/ct2/html/images/frame/icon.ico" rel="SHORTCUT ICON"/>
  <link href="/ct2/html/images/frame/ct.css" type="text/css" rel="stylesheet"/>
  <script type="text/javascript" src="/ct2/html/images/frame/ct.js" language="JavaScript">
  </script>
</head>

<body style="min-width:720px; margin-left:0px; margin-right:0px; margin-top:0px" onload="doLoadActions();">

<!-- small_banner -->
<div class="skip"><a href="#MainContent">Skip to Main Content</a></div>

<table class="layout_table banner_color" cellspacing="0" cellpadding="0" border="0" width="100%">
  <tr>
    <td align="left" style="padding:6px" nowrap>
      <a title="Show Home Page" href="/ct2/home">
        <img alt="ClinicalTrials.gov" src="/ct2/html/images/frame/small_title.gif" border="0"/>
      </a>
    </td>

    <td class="header3" align="right" style="padding:3px 12px 3px 3px;" nowrap>
            <a style="margin-left:1em;" title="Show Home Page" href="/ct2/home">Home</a>
            <a style="margin-left:1em;" title="Show Search Page" href="/ct2/search">Search</a>
            <a style="margin-left:1em;" title="Show Study Topics Page" href="/ct2/search/browse">Study Topics</a>
            <a style="margin-left:1em;" title="Show Glossary Page" href="/ct2/info/glossary">Glossary</a>
            <br/>
      <form method="get" action="/ct2/results" style="margin-top:0.5ex; margin-bottom:0px;">
        <input class="body3" type="text" name="term" alt="Quick Search" title="Quick Search" value="" size="30" maxlength="250"/>
        <input class="header3" type="submit" alt="Search" value="Search"/>
        
      </form>
    </td>
  </tr>
</table>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<a name="MainContent" id="skipnav"></a>


<!-- above_tabs -->
<div class="show_back_color">
<br/>

<div align="center" class="indent2" style="background-color:white; border-top:1px solid black; border-left:1px solid black; border-right:2px outset #aaaadd; border-bottom:2px outset #aaaadd; padding-top:1.0ex">

  <table class="layout_table header2" style="margin:0px" cellpadding="0" cellspacing="0" border="0">
    <tr valign="top">
      <td nowrap>Study 1 of 1 for search of:</td>
      <td align="left" style="padding-left:1em">NCT00697515</td>
    </tr>
  </table>

  <table class="layout_table header3" cellspacing="0" cellpadding="0" border="0">
    <tr valign="middle">
      <td nowrap>
                <img style="padding-right:0.5em" border="0" src="/ct2/html/images/frame/gray_left_arrow.gif" alt=""/>
              </td>
      <td nowrap>
                <span class="grayed_fore_color">Previous Study</span>
              </td>
      <td style="padding:1ex 2em 1ex 2em;" nowrap>
        <a title="Return to search result" href="/ct2/results?term=NCT00697515">Return to Search Results</a>
      </td>
      <td nowrap>
                <span class="grayed_fore_color">Next Study</span>
              </td>
      <td nowrap>
                <img style="padding-left:0.5em" border="0" src="/ct2/html/images/frame/gray_right_arrow.gif" alt=""/>
              </td>
    </tr>
  </table>

</div>
<br/>

</div>








<!-- tabs -->
<div class="show_back_color header3">
<table class="layout_table" cellpadding="0" cellspacing="0" border="0">
  <tr valign="bottom">
            <td valign="bottom"><img style="width:20px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="fore_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_fore.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_fore.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5ex 1.0em" nowrap >
            <span class="header2">Full Text View</span>
          </td>
          <td align="right"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img width="1" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td/>
          <td align="right"><img width="2" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Tabular View Page" href="/ct2/show/record/NCT00697515?term=NCT00697515&amp;rank=1" >Tabular View</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Study Results Page" href="/ct2/show/results/NCT00697515?term=NCT00697515&amp;rank=1" >Study Results</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td valign="bottom"><img style="width:50px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Related Studies Page" href="/ct2/show/related/NCT00697515?term=NCT00697515&amp;rank=1" >Related Studies</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom" width="100%"><img style="width:100%; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
  </tr>
</table>
</div>

<!-- Title section -->
<div class="indent3" align="center">

    <div class="header1" style="margin-top:3ex;">Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)</div>
  
      <div class="header2" style="margin-top:2ex; color:  red  ">
    This study has been completed.
  </div>
      
  
  <div style="margin-top:2ex">
    First Received: June 11, 2008 &nbsp;
          Last Updated: August 3, 2010 &nbsp;
      <a href="/ct2/archive/NCT00697515"
        title="Historical versions of study NCT00697515 on ClinicalTrials.gov Archive Site"
        onclick="openNewWindow('/ct2/archive/NCT00697515'); return false;">History of Changes</a>
      </div>

  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="50%" style="margin:2ex 0;">

        <tr>
      <th align="right" nowrap class="header3 pale_banner_color"> Sponsor: </th>
      <td align="left" nowrap class="body2"> Shire Pharmaceutical Development </td>
    </tr>
    
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">Information provided by: </th>
      <td align="left" nowrap class="body2">Shire Pharmaceutical Development</td>
    </tr>
    
    <tr>
      <th align="right" nowrap class="header3 pale_banner_color">ClinicalTrials.gov Identifier: </th>
      <td align="left" nowrap class="body2">NCT00697515</td>
    </tr>

  </table>

</div>
  
<!-- purpose_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Purpose</span>

<div class="indent2" style="margin-top:2ex">

  <div class="body3"><p style="margin-top:1ex; margin-bottom:1ex;">To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting</p></div><br/>

    <!-- condition, intervention, phase summary table -->
  <div align="center">
  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="80%">
    <tr align="left">
            <th class="header3 pale_banner_color">
        <a href="/ct2/help/conditions_desc" title="Help on Conditions field" onclick="openPopupWindow('/ct2/help/conditions_desc',false); return false;">Condition</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">Intervention</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/phase_desc" title="Help on Phase field" onclick="openPopupWindow('/ct2/help/phase_desc',false); return false;">Phase</a>
      </th>
          </tr>
    <tr align="left" valign="top">
            <td class="body3" nowrap>
                ADHD<br/>
              </td>
                  <td class="body3" nowrap>
                Drug: LDX<br/>
                Drug: Placebo<br/>
              </td>
                  <td class="body3" nowrap>
                Phase III<br/>
              </td>
          </tr>
  </table>
  </div>
  <br/>
  
  
  <table class="layout_table" style="margin-bottom:2ex;" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Study Type:</td>
      <td style="padding-left:1em">
        Interventional
              </td>
    </tr>
            <tr valign="top">
      <td nowrap>Study Design:</td>
      <td style="padding-left:1em">Allocation:&#160;Randomized<br/>Control:&#160;Placebo&#160;Control<br/>Endpoint&#160;Classification:&#160;Efficacy&#160;Study<br/>Intervention&#160;Model:&#160;Crossover&#160;Assignment<br/>Masking:&#160;Double&#160;Blind&#160;(Subject,&#160;Caregiver,&#160;Investigator)<br/>Primary&#160;Purpose:&#160;Treatment</td>
    </tr>
            <tr valign="top">
      <td nowrap style="padding-top:2ex">Official Title:</td>
      <td style="padding-left:1em; padding-top:2ex">A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)</td>
    </tr>
      </table>

    <!-- NLM links -->
  <br/>
  <div class="header3">Resource links provided by NLM:</div>
  <br/>
  <div class="indent3">

  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a href="http://www.nlm.nih.gov/medlineplus/" title="MedlinePlus site" onclick="openNewWindow('http://www.nlm.nih.gov/medlineplus/'); return false">MedlinePlus</a> related topics:
            <a style="padding-left:0.5em;" href="/ct2/bye/gQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9kioPzdUPedcx5676eBczWQozE61ykB-PeiNzWT7Pewc9S6hHSXNkWd7E." title="Attention&#160;Deficit&#160;Hyperactivity&#160;Disorder at MedlinePlus site" onclick="openNewWindow('/ct2/bye/gQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9kioPzdUPedcx5676eBczWQozE61ykB-PeiNzWT7Pewc9S6hHSXNkWd7E.'); return false">Attention&#160;Deficit&#160;Hyperactivity&#160;Disorder</a>
          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a href="http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp" title="Drug Information Portal" onclick="openNewWindow('http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp'); return false">Drug Information</a> available for:
            <a style="padding-left:0.5em;" href="/ct2/bye/yQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789ChzF6hHOB7LN61Pkd7zu6V." title="Lisdexamfetamine at ChemIDplus site" onclick="openNewWindow('/ct2/bye/yQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789ChzF6hHOB7LN61Pkd7zu6V.'); return false">Lisdexamfetamine</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/8QoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789ChzF6hHOB7LN61Pkd7zu6Dm5Q7Lzw-zvB1Pz." title="Lisdexamfetamine&#160;dimesylate at ChemIDplus site" onclick="openNewWindow('/ct2/bye/8QoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789ChzF6hHOB7LN61Pkd7zu6Dm5Q7Lzw-zvB1Pz.'); return false">Lisdexamfetamine&#160;dimesylate</a>
          </div>
  
  <a href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>


  
  <br/>
  
  </div>
  
    <!-- more details -->
  <br/>
  <div class="header3">Further study details as provided by Shire Pharmaceutical Development:</div>
  <br/>
  <div class="indent3">

        <!-- primary outcomes -->
    <div class="body3">Primary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase [&nbsp;Time&nbsp;Frame:&nbsp;2, 4, 8, 10, 12 and 14 hours post-dose on Day 7&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test.  The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session.  The scores range from 0-800 with higher scores indicating better performance.</div><br/>
            </ul>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="body3">Secondary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">PERMP Total Score by Timepoint in the Crossover Phase [&nbsp;Time&nbsp;Frame:&nbsp;2, 4, 8, 10, 12 and 14 hours post-dose on Day 7&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test.  The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly  in a 10-minute session.  The scores range from 0-800 with higher scores indicating better performance.</div><br/>
            <li style="margin-top:0.7ex;">PERMP Score for the Number of Math Problems Attempted by Timepoint in the Crossover Phase [&nbsp;Time&nbsp;Frame:&nbsp;2, 4, 8, 10, 12 and 14 hours post-dose on Day 7&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test.  The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly  in a 10-minute session.  The scores range from 0-800 with higher scores indicating better performance.</div><br/>
            <li style="margin-top:0.7ex;">PERMP Score for the Number of Math Problems Answered Correctly by Timepoint in the Crossover Phase [&nbsp;Time&nbsp;Frame:&nbsp;2, 4, 8, 10, 12 and 14 hours post-dose on Day 7&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test.  The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly  in a 10-minute session.  The scores range from 0-800 with higher scores indicating better performance.</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale With Prompts (ADHD-RS) Total Score at up to 28 Days in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and  7, 14, 21 and 28 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The Attention Deficit Hyperactivity Disorder Rating Scale with Prompts (ADHD-RS) consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.</div><br/>
            <li style="margin-top:0.7ex;">ADHD-RS With Prompts Total Score in the Crossover Phase [&nbsp;Time&nbsp;Frame:&nbsp;7 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The Attention Deficit Hyperactivity Disorder Rating Scale with Prompts (ADHD-RS) consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.</div><br/>
            <li style="margin-top:0.7ex;">Assessment of Clinical Global Impression-Severity of Illness (CGI-S) in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;7, 14, 21 and 28 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in the Crossover Phase [&nbsp;Time&nbsp;Frame:&nbsp;7 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline in the Brown Attention Deficit Disorder Scale (BADDS) Total Scores at 26 Days in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and 26 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The BADDS assessment consists of 40 items rated on a scale from 0 (never) to 3 (almost daily).  The total score ranges from 0 to 120 with increasing scores indicating more severe impairment.</div><br/>
            <li style="margin-top:0.7ex;">Level of Satisfaction With Study Treatment on Medication Satisfaction Questionnaire (MSQ) in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;26 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">MSQ is a survey rating the subject's level of satisfaction with the study treatment medication.</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline in Adult ADHD Impact Module (AIM-A) Question 1 Score at 26 Days in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and 26 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">AIM-A is a quality of life instrument.  Question 1 is 'On a scale of 1 to 10, how would you rate the overall quality of life right now?'  It is rated on a scale of 1 (worst) to 10 (best).</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline in AIM-A Question 4 Score at 26 Days in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and 26 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">AIM-A is a quality of life instrument. Question 4 is 'How much do you agree with this statement: Over the past few weeks, I've had more good days than bad days?'  This is rated on a scale of 1 (strongly agree) to 5 (strongly disagree).</div><br/>
            <li style="margin-top:0.7ex;">Change From Baseline in Systolic Blood Pressure at Up to 28 Days in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and 7, 14, 21 and 28 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Change From Baseline in Diastolic Blood Pressure at Up to 28 Days in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and 7, 14, 21 and 28 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Change From Baseline in Pulse Rate at Up to 28 Days in the Dose Optimization Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and 7, 14, 21 and 28 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Change From Baseline in Electrocardiogram Results (QTcF Interval) at 7 Days in the Crossover Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and 7 days&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">QTcF is the QT interval using Fridericia's correction formula.  QT interval is a measure of  time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval).  The QT interval has to be corrected in order to aid interpretation.</div><br/>
            </ul>
    </div>
    <br/>
    
    
    <table class="layout_table" style="margin-bottom:3ex;" cellpadding="0" cellspacing="0" border="0">
            <tr valign="top">
        <td nowrap> Enrollment:</td>
        <td style="padding-left:1em">142</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Start Date:</td>
        <td style="padding-left:1em">July 2008</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Completion Date:</td>
        <td style="padding-left:1em">December 2008</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Primary Completion Date:</td>
        <td style="padding-left:1em">December 2008 (Final data collection date for primary outcome measure)</td>
      </tr>
          </table>

        <!-- arms and groups table -->
    <div align="center">
    <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="100%">
      <tr align="left">
        <th class="header3 pale_banner_color">
          <a href="/ct2/help/arm_group_desc" title="Help on Arm Group field" onclick="openPopupWindow('/ct2/help/arm_group_desc',false); return false;">
             Arms           </a>
        </th>
                <th class="header3 pale_banner_color">
          <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">
            Assigned Interventions
          </a>
        </th>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          Lisdexamfetamine Dimesylate (LDX, SPD489): Active Comparator
<div class="indent2" style="margin-top:0.5ex">Intervention: Drug: LDX</div>
        </td>
                <td class="body3">
                      Drug: LDX
<div class="indent2" style="margin-top:0.5ex">oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          Placebo: Placebo Comparator
<div class="indent2" style="margin-top:0.5ex">Intervention: Drug: Placebo</div>
        </td>
                <td class="body3">
                      Drug: Placebo
<div class="indent2" style="margin-top:0.5ex">Placebo administered once-daily for one week during the adult workplace environment setting</div>
                  </td>
              </tr>
          </table>
    </div>
    <br/>
    
    
    <a name="desc" id="desc"></a>

    
    
        <!-- detailed description -->
    <span class="header3">Detailed Description:</span>
    <div class="body3"><p style="margin-top:1ex; margin-bottom:1ex;">This study has both an optimization and double-blind period</p></div>
        
  </div>
  
</div>
</div>
  
<!-- eligibility_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
  <img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Eligibility</span><br/>

  <br/>
  <div class="indent2">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0">
            <tr>
        <td nowrap>Ages Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">18 Years to 55 Years</td>
      </tr>
                  <tr>
        <td nowrap>Genders Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">Both</td>
      </tr>
                  <tr>
        <td nowrap>Accepts Healthy Volunteers: &nbsp; </td>
        <td style="padding-left:1em">No</td>
      </tr>
                </table>

    
        <div class="header3" style="margin-top:2ex">Criteria</div>
    <div class="indent2"><p style="margin-top:0ex; margin-bottom:1ex;">Inclusion Criteria:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Subject must be 18-55 years of age, inclusive at the time of consent.</li>
<li style="margin-top:0.7ex;">Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to comply with any applicable contraceptive requirements of the protocol.</li>
<li style="margin-top:0.7ex;">Subject meets Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD (diagnostic code 314.00 and 314.01) established by a comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria with at least 6 of the 9 subtype criteria met.  The Adult ADHD Clinical Diagnostic Scale version 1.2 (ACDS v1.2) will be utilized as the diagnostic tool.</li>
<li style="margin-top:0.7ex;">Subject has a Baseline score of &gt; or equal to 28 using the Adult ADHD-RS with prompts.</li>
<li style="margin-top:0.7ex;">Subject must have a minimum level of intellectual functioning, as determined by an Intelligent Quotient (IQ) score of 80 or above based on the Kaufman Brief Intelligence Test (KBIT).</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Subject has a current comorbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms. Comorbid psychiatric diagnoses will be established by the psychiatric evaluation that includes the Structured Clinical Interview for DSM-IV-TR disorders (SCID-I).</li>
<li style="margin-top:0.7ex;">Subjects who are currently considered a suicide risk, any subject who has previously made a suicide attempt or those who are currently demonstrating active suicidal ideation.</li>
<li style="margin-top:0.7ex;">Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.</li>
<li style="margin-top:0.7ex;">Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, transient ischemic attack or stroke or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.</li>
<li style="margin-top:0.7ex;">Subject has current abnormal thyroid function, as defined as abnormal Screening thyroid stimulating hormone.  Treatment with a stable dose of thyroid medication for at least 3 months is permitted.</li>
<li style="margin-top:0.7ex;">Subject has a history of moderate to severe hypertension or has a resting sitting systolic blood pressure &gt;139mmHg or diastolic blood pressure &gt;89mmHg.</li>
<li style="margin-top:0.7ex;">Subject has a documented allergy, hypersensitivity, or intolerance to amphetamines.</li>
<li style="margin-top:0.7ex;">Subject has failed to respond to one or more adequate courses (dose and duration) of amphetamine therapy.</li>
<li style="margin-top:0.7ex;">Subject has glaucoma.</li>
<li style="margin-top:0.7ex;">Subject is taking other medications that have central nervous system (CNS) effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors (during or within 14 days of test or reference product administration).  Stable use of bronchodilator inhalers is not exclusionary.</li>
<li style="margin-top:0.7ex;">Subject is female and pregnant or lactating.</li>
</ul></div>
    
  </div>

</div>

  
<!-- location_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Contacts and Locations</span><br/>

<div class="indent2" style="margin-top:2ex">

    Please refer to this study by its ClinicalTrials.gov identifier: NCT00697515<br/>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
  <a name="locn" id="locn"></a>

  
  
    <div class="header3" style="margin-top:2ex">Locations</div>
  <table class="layout_table indent2" cellspacing="0" cellpadding="0" border="0">
            <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, Arkansas</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Clinical Study Centers, LLC</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Little Rock, Arkansas, United States, 72205  </td></tr>
                    <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, California</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>University of CA, Irvine Child Development Center</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Irvine, California, United States, 92612  </td></tr>
                    <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, Kansas</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Vince &amp; Associates Clinical Research</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Overland Park, Kansas, United States, 66212  </td></tr>
                    <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, Nevada</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Center for Psychiatry &amp; Behavioral Medicine, Inc</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Las Vegas, Nevada, United States, 89128  </td></tr>
                    <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, Texas</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Bayou City Research, LTD</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Houston, Texas, United States, 77007  </td></tr>
              </table>
  
  
  <!-- sponsors -->
    <div class="header3" style="margin-top:2ex">Sponsors and Collaborators</div>
    <div class="indent2" style="margin-top:1ex">Shire Pharmaceutical Development</div>
    
  <!-- investigators -->
    <div class="header3" style="margin-top:2ex">Investigators</div>
  <table class="layout_table indent2" cellspacing="0" cellpadding="0" border="0">
        <tr>
      <td style="padding:1ex 1em 0px 0px" nowrap>Principal Investigator:</td>
      <td style="padding:1ex 1em 0px 0px" nowrap>Tim Wigal, PhD</td>
            <td style="padding:1ex 1em 0px 0px" nowrap>University of CA, Irvine Child Development Center</td>
                </tr>
      </table>
  

</div>
</div>

<!-- more_info_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; More Information</span>

<div class="indent2">
  <br/>


    Additional Information:
    <div class="indent2" style="margin-top:2ex">
        <a href="/ct2/bye/NQoPWw4lZX-i-iSxN6hju6c9cXc9EB7gZdDq-B7azwUPFXNkWd7E/7P5P3noyzBcGvdY3edN6ZwNLkihzZdJ" title="FDA recall information" onclick="openNewWindow('/ct2/bye/NQoPWw4lZX-i-iSxN6hju6c9cXc9EB7gZdDq-B7azwUPFXNkWd7E/7P5P3noyzBcGvdY3edN6ZwNLkihzZdJ'); return false">FDA recall information</a>&nbsp
    <img src="/ct2/html/images/frame/exit.bmp" alt="This link exits the ClinicalTrials.gov site"/>
      </div>
    <div class="indent2" style="margin-top:2ex">
        <a href="/ct2/bye/WQoPWw4lZX-i-iSxN6hju6c9cXWLz6oikihglXLg3P5H87DqSR4t-X-gk6NHWTCt-XNkWdV/kP5P3njLz6hz0B7EJ8oyZ6oH0iY3CB76zio5JV7azwUPF" title="FDA Medical Product Safety Alerts" onclick="openNewWindow('/ct2/bye/WQoPWw4lZX-i-iSxN6hju6c9cXWLz6oikihglXLg3P5H87DqSR4t-X-gk6NHWTCt-XNkWdV/kP5P3njLz6hz0B7EJ8oyZ6oH0iY3CB76zio5JV7azwUPF'); return false">FDA Medical Product Safety Alerts</a>&nbsp
    <img src="/ct2/html/images/frame/exit.bmp" alt="This link exits the ClinicalTrials.gov site"/>
      </div>
    <div class="indent2" style="margin-top:2ex">
        <a href="/ct2/bye/cQoPWw4lZX-i-iSxcT16kdUgzXNgZdD9E6hBZwoyzwcgSQ7yedNi2Q7xNd-ymB1PedcOuwhPN/DP5P3X7GEwoyZiNH5nhakBNHv" title="FDA-approved label" onclick="openNewWindow('/ct2/bye/cQoPWw4lZX-i-iSxcT16kdUgzXNgZdD9E6hBZwoyzwcgSQ7yedNi2Q7xNd-ymB1PedcOuwhPN/DP5P3X7GEwoyZiNH5nhakBNHv'); return false">FDA-approved label</a>&nbsp
    <img src="/ct2/html/images/frame/exit.bmp" alt="This link exits the ClinicalTrials.gov site"/>
      </div>
    <br/>
  
    Publications:
  <div class="indent2">
            <div style="margin-top:2ex">
            Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Wigal T, Brams M, Gasior M, et al. Behavioral and Brain Functions, 2010; 6:34
          </div>
              </div>
  <br/>
  
    Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
  <div class="indent2">
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9R0tOg0jLK4R." title="Brown TE, Brams M, Gao J, Gasior M, Childress A. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med. 2010 Sep;122(5):7-17." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9R0tOg0jLK4R.'); return false">Brown TE, Brams M, Gao J, Gasior M, Childress A. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med. 2010 Sep;122(5):7-17.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9R0tLgFBEKCj." title="Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J; 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010 Jun 24;6:34." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9R0tLgFBEKCj.'); return false">Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J; 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010 Jun 24;6:34.</a>
          </div>
      </div>
  <br/>
  
  
  <table class="layout_table" style="margin-top:1ex" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Responsible Party:</td>
      <td style="padding-left:1em">Shire Pharmaceutical Development Inc. ( Timothy Whitaker, M.D., Clinical Research and Development - VP of Global Clinical Medicine )</td>
    </tr>
        <tr valign="top">
      <td nowrap>ClinicalTrials.gov Identifier:</td>
      <td style="padding-left:1em">
        <a title="Current version of study NCT00697515 on ClinicalTrials.gov" href="http://clinicaltrials.gov/ct2/show/NCT00697515">NCT00697515</a> &nbsp; &nbsp;
        <a href="/ct2/archive/NCT00697515"
          title="Historical versions of study NCT00697515 on ClinicalTrials.gov Archive Site"
          onclick="openNewWindow('/ct2/archive/NCT00697515'); return false;">History of Changes</a>
      </td>
    </tr>
            <tr valign="top">
      <td nowrap>Other Study ID Numbers:</td>
      <td style="padding-left:1em">SPD489-316</td>
    </tr>
            <tr valign="top">
      <td nowrap>Study First Received:</td>
      <td style="padding-left:1em">June 11, 2008</td>
    </tr>
            <tr valign="top">
      <td nowrap>Results First Received:</td>
      <td style="padding-left:1em">November 20, 2009</td>
    </tr>
            <tr valign="top">
      <td nowrap>Last Updated:</td>
      <td style="padding-left:1em">August 3, 2010</td>
    </tr>
            <tr valign="top">
      <td nowrap>Health Authority:</td>
      <td style="padding-left:1em">United States: Food and Drug Administration</td>
    </tr>
      </table>

  
  <!-- keywords -->
  
  <!-- mesh terms -->
    <br/>
  Additional relevant MeSH terms:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    Hyperkinesis<br/>
                    Attention Deficit Disorder with Hyperactivity<br/>
                    Dyskinesias<br/>
                    Neurologic Manifestations<br/>
                    Nervous System Diseases<br/>
                    Signs and Symptoms<br/>
                    Attention Deficit and Disruptive Behavior Disorders<br/>
                    Mental Disorders Diagnosed in Childhood<br/>
                    Mental Disorders<br/>
                    Dextroamphetamine<br/>
                  </td>
                <td width="50%" style="padding-left:1em">
                    Dopamine Uptake Inhibitors<br/>
                    Dopamine Agents<br/>
                    Neurotransmitter Agents<br/>
                    Molecular Mechanisms of Pharmacological Action<br/>
                    Pharmacologic Actions<br/>
                    Neurotransmitter Uptake Inhibitors<br/>
                    Physiological Effects of Drugs<br/>
                    Central Nervous System Stimulants<br/>
                    Central Nervous System Agents<br/>
                    Therapeutic Uses<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  
  <br/>

    <span class="body3">ClinicalTrials.gov processed this record on March 02, 2011</span><br/>
  
  <br/>

</div>
</div>


<!-- Footer -->
<div class="skip"><a href="#MainContent">Back to top of Main Content</a></div>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<div align="center" class="footer">
  <br/>
  <a href="/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00697515%3Fterm%3DNCT00697515%26rank%3D1" onclick="openPopupWindow('/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00697515%3Fterm%3DNCT00697515%26rank%3D1',true); return false;">Contact Help Desk</a><br/>
  <a href="http://www.lhncbc.nlm.nih.gov">Lister Hill National Center for Biomedical Communications</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a>,<br/>
  <a href="http://www.nih.gov/">U.S. National Institutes of Health</a>,&nbsp;
  <a href="http://www.hhs.gov/">U.S. Department of Health &amp; Human Services</a>,<br/>
  <a href="http://www.usa.gov/">USA.gov</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a>,&nbsp;
  <a href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a><br/>

  <br/>
  <a href="http://www.nih.gov/"><img alt="U.S. National Institutes of Health" src="/ct2/html/images/frame/nih_logo.gif" border="0"/></a>
  <a href="http://www.nlm.nih.gov/"><img alt="U.S. National Library of Medicine" src="/ct2/html/images/frame/nlm_logo.gif" border="0"/></a>
  <a href="http://www.hhs.gov/"><img alt="U.S. Department of Health &amp; Human Services" src="/ct2/html/images/frame/hhs_logo.gif" border="0"/></a>

  <br/>
  <br/>
  <br/>
  <br/>
  <a href="/ct2/crawl" class="skip">Links to all studies - primarily for crawlers</a>
</div>

<!-- 2011:03:03 23:49:08.454  RRc0qzu:SRc0cjJ:I4Ya2XK -->
</body>
</html>
